Bullseye Asset Management LLC Decreases Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Bullseye Asset Management LLC reduced its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 26.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,201 shares of the company’s stock after selling 12,799 shares during the quarter. TransMedics Group comprises approximately 2.6% of Bullseye Asset Management LLC’s investment portfolio, making the stock its 12th biggest holding. Bullseye Asset Management LLC’s holdings in TransMedics Group were worth $5,684,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the business. Amalgamated Bank boosted its stake in TransMedics Group by 6.7% in the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares in the last quarter. Harbour Capital Advisors LLC raised its holdings in shares of TransMedics Group by 1.7% in the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after buying an additional 81 shares during the last quarter. Signaturefd LLC lifted its stake in shares of TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the period. Arizona State Retirement System grew its holdings in shares of TransMedics Group by 2.1% during the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after buying an additional 186 shares during the last quarter. Finally, Venturi Wealth Management LLC increased its position in shares of TransMedics Group by 33.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after acquiring an additional 219 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $69.84 on Tuesday. The stock has a fifty day simple moving average of $101.87 and a 200-day simple moving average of $133.40. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The stock has a market cap of $2.34 billion, a PE ratio of 74.30 and a beta of 2.06. TransMedics Group, Inc. has a twelve month low of $66.10 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same quarter last year, the business posted ($0.12) EPS. The firm’s revenue for the quarter was up 63.7% on a year-over-year basis. Equities analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on TMDX shares. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Tuesday, December 3rd. TD Cowen reduced their price target on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Finally, JPMorgan Chase & Co. reduced their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $131.80.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the sale, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. The trade was a 90.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $9,457,269.06. The trade was a 12.27 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,042 shares of company stock worth $3,563,985. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.